We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Incidence of Acute Lung Injury: The Alien Study (ALIEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00736892
Recruitment Status : Completed
First Posted : August 18, 2008
Last Update Posted : October 11, 2018
Sponsor:
Information provided by (Responsible Party):
Jesus Villar, Dr. Negrin University Hospital

Brief Summary:
Acute lung injury is a clinical syndrome of rapid onset of acute respiratory failure. It represents a significant public health issue. Patients with acute lung injury require admission into critical care units for advanced life support and utilize considerable health care resources. Published epidemiological studies on acute lung injury in the last 20 years are difficult to compare because they used different definitions and length of time for evaluation. Less than five studies have collected information for an entire year, and none of them have evaluated the degree of oxygenation failure under standard settings. We will perform a one-year prospective audit of all patients admitted with acute lung injury in almost 40 ICUs in Spain.

Condition or disease
Acute Lung Injury

Detailed Description:

Acute lung injury (ALI) is a clinical syndrome of rapid onset of non-cardiogenic pulmonary edema manifested clinically by hypoxemia (PaO2/FiO2≤300 mmHg) and bilateral pulmonary infiltrates. When the hypoxemia is severe (PaO2/FiO2≤200 mmHg) it is termed the acute respiratory distress syndrome (ARDS). It represents a significant public health issue. Patients with ALI or ARDS require admission into critical care units for advanced life support and utilize considerable health care resources.

An immense plethora of translational knowledge has been acquired since the first description of ARDS in 1967. However, estimates of the incidence of ARDS and ALI have varied widely, and the true magnitude of this health problem still remains unclear. Current estimates of the incidence of ALI/ARDS range from 15 to 80 cases per 100.000 population, or almost 40.000 cases per year in Spain. Combined mortality rates for ALI/ARDS range between 30-45%. ALI and ARDS occur as a complication or as the primary cause of critical illness in patients, usually after severe infection or trauma.

Published epidemiological studies on ALI and ARDS in the last 20 years are difficult to compare. Some reports have used different definitions for ALI and ARDS and others have evaluated the incidence during a short period of time (from days to several weeks) and then extrapolated their data to estimates of a one-year incidence. Very few studies have collected information for an entire year, and none of them have evaluated the degree of hypoxemia under standard ventilatory settings, as it has been proposed recently by the HELP Network (Am J Respir Crit Care Med 2007; 176:795-804).

As a result, we propose to perform a one-year prospective audit of all ALI and ARDS patients managed in 40 ICUs from 17 Spanish provinces (15 provinces in the mainland and 2 provinces in the Canary Islands). We intend to collect data from all patients admitted with or developing ALI/ARDS with the aim to understand the epidemiology and natural history of acute lung injury. These provinces are scattered through the Spain and are representative of the demographic differences across the country.

Layout table for study information
Study Type : Observational
Actual Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Acute Lung Injury: Epidemiology and Natural History. The ALIEN Study
Actual Study Start Date : September 2008
Actual Primary Completion Date : March 2010
Actual Study Completion Date : May 2010


Group/Cohort
A
All patients meeting the American European Consensus definition of acute lung injury will be included, regardless of etiology of respiratory failure. Specifically, all patients with rapid onset of acute lung injury not of cardiac origin (no indication of heart failure or a pulmonary capillary wedge pressure of greater than 18 mmHg, with pulmonary infiltrates in all four quadrants and a PaO2/FIO2 of > 200 to <300 mmHg or ≤ 200 mmHg.



Primary Outcome Measures :
  1. Incidence of acute lung injury and the acute respiratory distress syndrome [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Risk factor associated with acute lung injury [ Time Frame: 12 months ]
  2. Mortality rates of acute lung injury, acute respiratory distress syndrome and combined [ Time Frame: 12 months ]
  3. Identification of clinical data associated with the highest or lowest mortality [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients admitted into intensive care units of participating hospitals across Spain meeting the American-European Consensus Conference definition of acute lung injury.
Criteria

Inclusion Criteria:American-European Consensus Conference Definition criteria for acute lung injury:(i) rapid onset of acute lung injury not of cardiac origin; (ii) bilateral pulmonary infiltrates on chest X ray; (iii) PaO2/FIO2<300 mmHg.

Exclusion Criteria: None


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00736892


Locations
Layout table for location information
Spain
Hospital Universitario Dr. Negrin
Las Palmas de Gran Canaria, Canary Islands, Spain, 35010
Sponsors and Collaborators
Villar, Jesus, M.D.
Investigators
Layout table for investigator information
Principal Investigator: Jesus Villar, MD, PhD Hospital Universitario Dr. Negrin, Las Palmas, Spain
Principal Investigator: Robert M Kacmarek, PhD Massachusetts General Hospital, Boston, USA
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Jesus Villar, Director of Research, Dr. Negrin University Hospital
ClinicalTrials.gov Identifier: NCT00736892    
Other Study ID Numbers: 2008-0915-EPI
First Posted: August 18, 2008    Key Record Dates
Last Update Posted: October 11, 2018
Last Verified: October 2018
Keywords provided by Jesus Villar, Dr. Negrin University Hospital:
Acute lung injury
Acute respiratory distress syndrome
Mechanical ventilation
Prognosis
Definitions
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Injury
Acute Lung Injury
Wounds and Injuries
Lung Diseases
Respiratory Tract Diseases
Thoracic Injuries